Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma

doi:10.5306/wjco.v12.i12.1215

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4617)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

470

WORD

182

HTML

1531

Figures (1-3)

209

Tables (1-2)

217

Sum=2609

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

310

Download

556

Sum=866

Publishing Process of This Article

Item

Count

Browse

404

Download

738

Sum=1142

Dec 24, 2021 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Oncol. Dec 24, 2021; 12(12): 1215-1226
Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1215

Table 1 Patients, tumors and treatment characteristics

Patient ID	Gender	Age	сТ	сN	Stage	CRM	EMV	Tumor location	RAS/RAFstatus	Total RT dose, Gy	Chemosensibilization¹	RECIST	Surgery	MRI TRG	Mandard TRG	ypT	уN	Progression²	Follow-up, mo	ctDNA positive at baseline
Patient ID	Gender	Age	сТ	сN	Stage	CRM	EMV	Tumor location	RAS/RAFstatus	Total RT dose, Gy	Chemosensibilization¹	RECIST	Surgery	MRI TRG	Mandard TRG	ypT	уN	Yes/no	Follow-up, mo	ctDNA positive at baseline
ArAS	M	44	3	1	3	No	No	L	KRAS G12S	50	Yes	SD	Yes	III	NA	3	0	No	6.90	No
GaZM	F	66	3	2	3	Yes	No	U-M	KRAS G13D	46	Yes	PR	Yes	IV	4	4	1	No	4.03	No
DaKS	M	73	4	1	3	Yes	No	L	KRAS G12A	25 (short course)	No	PD	No	IV	NA	NA	NA	Yes	4.73	Yes
ArTP	F	81	4	1	3	Yes	Yes	L	KRAS Q61L	50	No	SD	Yes	III	3	3	0	Nd	5.80	Yes
MaLI	F	78	3	1	3	No	No	L	NRAS G12D	25(short course)	No	PD	No	IV	NA	NA	NA	Yes	3.97	Yes
MaNK	F	48	3	2	3	No	Yes	M	KRAS G12D	50	Yes	SD	Yes	III	2	3	2	No	6.57	Yes
ZuNM	F	63	3	2	3	No	No	L-M	BRAF V600E	44	Yes	PR	Yes	II	2	3	0	No	5.13	No
MiMF	F	74	3	1	3	No	Yes	M	NRAS G12D	25(short course)	No	PR	No	III	NA	NA	NA	No	3.13	No
SaVV	M	65	3	1	3	Yes	No	L-M	NRAS Q61R	50	Yes	SD	No	III	NA	NA	NA	Nd	1.13	No

¹Capecitabine 825 mg/m² twice daily was delivered on the days of RT (D1-5, D8-12, D 15-19, D22-26, D29-33).

²Disease status at March 1,.2021; Nd – lost from follow-up.

Tumor localization: U: Upper rectum, M: Middle rectum, L: Lower rectum; EMV: Extramural venous invasion; CRM: Circumferential resection margin; TRG: Tumor regression grade; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not evaluated; ctDNA: Circulating tumor DNA.

Citation: Kuligina E, Moiseyenko F, Belukhin S, Stepanova E, Zakharova M, Chernobrivtseva V, Aliev I, Sharabura T, Moiseyenko V, Aleksakhina S, Laidus T, Martianov A, Kholmatov M, Whitehead A, Yanus G, Imyanitov E. Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma. World J Clin Oncol 2021; 12(12): 1215-1226
URL: https://www.wjgnet.com/2218-4333/full/v12/i12/1215.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i12.1215